Patients on checkpoint inhibitors may need bone screening, endocrinologist suggests
A new Australian study shows an association between immune checkpoint inhibitor therapy and osteoporosis.
Emerging evidence shows an association between immune checkpoint inhibitor therapy and osteoporosis, with the agents linked to increased fracture risk in cancer patients.
The latest research, in BMJ Oncology, found that the rate of major osteoporotic fracture increased in patients with melanoma early after initiation of immunotherapy, such as pembrolizumab.
